News
05-07-2014, 12:52 AM
NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced that it has received a Class III Medical Device License from Health Canada, clearing the company to market its Prosigna Breast Cancer Prognostic Gene Signature Assay for assessing a woman's 10-year risk of distant recurrence and accurately identifying the intrinsic biologic subtype of the tumor.
More... (http://www.news-medical.net/news/20140507/NanoString-receives-license-from-Health-Canada-to-market-Prosigna-Breast-Cancer-Prognostic-Gene-Signature-Assay.aspx)
More... (http://www.news-medical.net/news/20140507/NanoString-receives-license-from-Health-Canada-to-market-Prosigna-Breast-Cancer-Prognostic-Gene-Signature-Assay.aspx)